Arthneeti

Ortin Global Q2 FY27 Share Price & Earnings Call Analysis

₹13.97-0.07% today
Market cap
₹11 Cr
ROE
-48.45%
Price to sales
34.48
Debt to equity
0.81
52W high / low
₹19.9 / ₹11.2
Sales growth (5Y)
-58.54%
EBITDA margin
-269.70%
Net profit margin
-780.00%
Promoter holding
1.24%
Sales (last year)
₹0 Cr

Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations.[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Ortin Global rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,041 Cr33.1
240%+Up 2%+₹492 Cr19.6
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,347 Cr—
540%+Flat₹8,432 Cr32.4
640%+Flat₹4,295 Cr—

Sign up free to see every company in the sector ranking and track Ortin Global.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Ortin Global

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Ortin Global

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +7.36%1.23%1.23%1.23%1.23%1.23%1.23%1.23%1.23%1.23%1.23%1.24%
FIIs +0.00%0.00%6.25%6.25%6.25%6.53%6.53%1.68%1.68%1.68%1.80%0.67%
Public +92.64%98.76%92.53%92.52%92.52%92.24%92.24%97.08%97.09%97.10%96.96%98.09%
No. of Shareholders12,31412,19211,95212,16512,09412,14412,03412,06011,83411,45211,38311,151

Pros & Cons

Ortin Global

Key positives and risks surfaced from the company insights section.

Pros
  • Stock is trading at 17.4 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -58.5% over past five years.
  • Promoter holding is low: 1.24%
  • Company has a low return on equity of -73.1% over last 3 years.
  • Contingent liabilities of Rs.24.3 Cr.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 730 days.
  • Promoter holding has decreased over last 3 years: -6.13%
  • Working capital days have increased from 1,625 days to 2,993 days
Raw Insights
  • Stock is trading at 17.4 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -58.5% over past five years.
  • Promoter holding is low: 1.24%
  • Company has a low return on equity of -73.1% over last 3 years.
  • Contingent liabilities of Rs.24.3 Cr.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 730 days.
  • Promoter holding has decreased over last 3 years: -6.13%
  • Working capital days have increased from 1,625 days to 2,993 days

Financials of Ortin Global

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +0.270.140.300.210.050.030.090.080.010.010.300.010.04
YoY Sales growth-65.82%-88.03%-79.87%-86.62%-81.48%-78.57%-70.00%-61.90%-80.00%-66.67%+233.33%-87.50%+300.00%
Expenses +1.172.743.350.310.500.160.250.240.510.060.310.340.31
Operating Profit-0.90-2.60-3.05-0.10-0.45-0.13-0.16-0.16-0.50-0.05-0.01-0.33-0.27
OPM %-333.33%-1,857.14%-1,016.67%-47.62%-900.00%-433.33%-177.78%-200.00%-5,000.00%-500.00%-3.33%-3,300.00%-675.00%
Other Income +0.000.000.000.000.000.020.000.000.000.000.000.000.00
Interest0.150.140.080.000.02-0.010.000.000.000.000.000.000.00
Depreciation0.060.060.050.000.000.000.000.000.000.000.000.000.00
Profit before tax-1.11-2.80-3.18-0.10-0.47-0.10-0.16-0.16-0.50-0.05-0.01-0.33-0.27
Tax %1.80%-0.71%30.19%0.00%0.00%10.00%0.00%6.25%0.00%0.00%0.00%0.00%0.00%
Net Profit +-1.12-2.79-4.14-0.10-0.47-0.11-0.16-0.18-0.50-0.05-0.01-0.34-0.27
EPS in Rs-1.38-3.43-5.09-0.12-0.58-0.14-0.20-0.22-0.61-0.06-0.01-0.42-0.33

Financials of Ortin Global

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +60.2962.7261.5779.63167.51197.368.168.236.002.010.340.100.36
Sales growth-10.01%+4.03%-1.83%+29.33%+110.36%+17.82%-95.87%+0.86%-27.10%-66.50%-83.08%-70.59%+71.43%
Expenses +53.8056.8356.1274.22160.83191.666.927.855.476.401.231.131.02
Operating Profit6.495.895.455.416.685.701.240.380.53-4.39-0.89-1.03-0.66
OPM %10.76%9.39%8.85%6.79%3.99%2.89%15.20%4.62%8.83%-218.41%-261.76%-1,030.00%-183.33%
Other Income +0.000.570.320.450.130.180.050.190.01-1.980.060.310.00
Interest3.523.422.943.493.223.210.870.810.400.480.000.000.00
Depreciation1.641.651.701.691.751.960.290.290.250.230.010.000.00
Profit before tax1.331.391.130.681.840.710.13-0.53-0.11-7.08-0.84-0.72-0.66
Tax %32.33%41.01%55.75%0.00%30.43%181.69%-623.08%-24.53%-18.18%13.56%1.19%2.78%
Net Profit +0.900.830.500.681.28-0.560.95-0.40-0.09-8.04-0.85-0.74-0.67
EPS in Rs0.530.490.300.400.76-0.331.17-0.49-0.11-9.89-1.05-0.91-0.82
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials of Ortin Global

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital16.9416.9416.9416.9416.9416.948.138.138.138.138.138.138.13
Reserves5.506.336.467.148.156.883.222.832.73-5.31-6.15-6.89-7.50
Borrowings +20.9620.8517.3417.3419.4719.576.946.146.451.800.251.011.23
Other Liabilities +23.8721.2220.7932.2460.5373.132.973.613.892.051.552.402.65
Total Liabilities67.2765.3461.5373.66105.09116.5221.2620.7121.206.673.784.654.51
Fixed Assets +21.8321.6320.6920.0321.2922.4514.3814.2113.960.010.000.010.00
CWIP0.000.000.350.400.530.430.430.430.430.000.000.000.00
Investments0.030.030.070.080.080.070.000.000.000.000.000.000.00
Other Assets +45.4143.6840.4253.1583.1993.576.456.076.816.663.784.644.51
Total Assets67.2765.3461.5373.66105.09116.5221.2620.7121.206.673.784.654.51

Financials of Ortin Global

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-1.380.521.941.566.523.3018.032.15-0.25-4.79-0.41-0.56
Cash from Investing Activity +0.22-0.86-1.26-0.90-3.27-3.090.07-0.130.0112.000.000.04
Cash from Financing Activity +1.730.27-0.820.07-2.89-1.33-9.86-0.480.90-3.490.330.75
Net Cash Flow0.58-0.07-0.140.730.37-1.128.251.550.663.72-0.090.23
Free Cash Flow-1.38-0.920.830.773.380.2818.032.02-0.247.21-0.41-0.52
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit-14%17%47%40%104%72%1,454%566%-47%80%46%54%

Financials of Ortin Global

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days103.7753.1390.35100.1582.4368.71174.90143.69208.05321.42279.12730.00
Inventory Days192.30148.72158.21152.21100.07117.80169.10136.29279.944.9234.760.00
Days Payable151.0924.82108.10143.09145.12155.80123.8261.88166.897.8769.52
Cash Conversion Cycle144.97177.04140.45109.2837.3830.70220.17218.10321.10318.47244.36730.00
Working Capital Days29.0016.2437.2941.4816.8211.24-87.22-109.10-43.19357.741,524.412,993.00
ROCE %12.07%10.92%9.57%9.44%11.77%8.94%3.24%1.58%1.80%-40.58%-25.11%-33.93%

Continue your research

What Ortin Global's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Alkem Lab (Q2 FY27)

    Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY. Key investor presentation takeaways from Alkem Laboratories Ltd's Q2 FY27 investor pres

  • Caplin Point Laboratories Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26). Key investor presentation takeaways from Caplin Point Labor

  • Bal Pharma (Q2 FY27)

    Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of…

  • Bafna Pharmaceuticals (Q2 FY27)

    INR 3,546.82 Lakhs, approximately 34.4% increase. Key results statement takeaways from Bafna Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals